Depression is a syndrome characterized by a sad mood exceeding normal sadness or grief, and major depressive disorder (MDD, major depression) has been associated with considerable morbidity and mortality[@b1] and has been projected to become the second-leading cause of disability worldwide by 2020 after ischemic heart disease[@b2]. Recent studies have implicated several genes in the development of depression[@b3], although the search for specific genes that confer this risk has been frustrating, as no genetic abnormality has been identified with any certainty[@b4]. In addition, several studies have suggested that environmental factors also contribute to an increased risk of depression, including exposure to poverty[@b5], toxic factors[@b6], stress[@b7], and infectious agents[@b8].

There is a long-standing belief that infectious agents can produce depression[@b8]; for example, infections occurring during prenatal and perinatal stages have produced serious neuropsychiatric consequences[@b9], and early cross-sectional studies have demonstrated significantly elevated antibody titers against herpes simplex virus (HSV) in depressed patients[@b10]. Therefore, there may be an association between certain infectious agents and the development of depression that could provide a means by which to improve both depression outcomes and prevention.

Despite the substantial number of studies on this subject, contradictory findings have arisen. Early clinical studies supported an association of raised antibody titers against HSV[@b10] and Epstein-Barr virus[@b11] with depression. However, opposing results have also been reported that reveal no significant association between antibodies to HSV[@b12], influenza[@b13], or neurotropic viruses[@b14] with depression. Therefore, this study aims to systematically analyze the current evidence regarding associations between a set of infectious agents and depression.

Results
=======

According to aforementioned inclusion and exclusion criteria, 28 studies were finally considered eligible for inclusion in the meta-analysis ([Fig. 1](#f1){ref-type="fig"}, [Table 1](#t1){ref-type="table"}). Forest plots comparing infections with Borna disease virus (BDV) ([Fig. 2](#f2){ref-type="fig"}), human herpesvirus (HHV, *Herpesviridae*) ([Fig. 3](#f3){ref-type="fig"}), *Chlamydiaceae* ([Fig. 4](#f4){ref-type="fig"}), hepatitis B virus (HBV) ([Fig. 5A](#f5){ref-type="fig"}) and *Toxoplasma gondii* ([Fig. 5B](#f5){ref-type="fig"}) between depressed patients and controls are also provided.

BDV
---

BDV is the most widely-studied infectious agent associated with depression. A total of 15 studies were included, two of which stood out as those of highest weight[@b15] and quality[@b16] ([Fig. 2](#f2){ref-type="fig"}, [Table 1](#t1){ref-type="table"}). The narrowest CI 95% range study was a Bode[@b17] study on account of the large amount of participants included. The estimated combined OR was 3.25 (CI 95%: 1.61--6.55; *P* = 0.001), indicating a statistically significant association between BDV infection and depression. After performing heterogeneity testing between these studies, the resulting χ^2^~exp~ = 25.96 (14 degrees of freedom, *P* = 0.026) indicated a trend for significant heterogeneity among OR values obtained from different studies. This finding is corroborated by a *I^2^* coefficient of 46.1% (CI 95%: 0.02--0.71), which indicates that 46.1% of the variability between the OR values obtained from different studies was due to a moderate level of heterogeneity between them (\<75%). Using meta-regression, we found that the technique used to detect BDV infection did not influence the OR value (*P* = 0.494). Thus, the OR values of the studies that detected RNA from blood or PBMCs (OR = 8.55, CI 95%: 2.48--29.44) were not significantly different from the OR values obtained in studies in which serum antibodies were detected (OR = 2.39, CI 95%: 1.01--5.66). Begg\'s and Egger\'s tests were both performed, and the findings therefrom were not significant (*P* = 0.805 and *P* = 0.297, respectively), indicating no publication bias.

HHV
---

Six HHVs -- herpes simplex virus-1 (HSV-1, HHV-1), herpes simplex virus-2 (HSV-2, HHV-2), varicella zoster virus (VZV, HHV-3), Epstein-Barr virus (EBV, HHV-4), cytomegalovirus (CMV, HHV-5), and roseolovirus (HHV-6) -- were analyzed in the current study ([Fig. 3](#f3){ref-type="fig"}). As to HSV-1, significant differences were found (*P* = 0.030) from the analysis of four studies that compared HSV-1 infection in depressed patients and healthy controls ([Fig. 3A](#f3){ref-type="fig"}). The Pokorny et al.[@b12] study was assigned the highest weight. When heterogeneity tests were performed, a χ^2^~exp~ = 5.47 was obtained with three degrees of freedom and a *P* = 0.140, indicating that the differences between the studies can be attributed to randomness. This finding was further corroborated by an *I^2^* coefficient of 45.2% (CI 95%: 0--0.82), indicating that there was not substantial inconsistency. The Begg\'s test result was not significant (*P* = 1.000), indicating no publication bias. A similar result was obtained after Egger\'s test (*P* = 0.986). With respect to VZV, significant differences were found (OR = 2.07; CI 95%: 1.01--4.28; *P* = 0.048) from the analysis of three low-quality studies that compared VZV infection in depressed patients and healthy controls ([Fig. 3B](#f3){ref-type="fig"}). The Lycke et al.[@b18] study was assigned the highest weight and relative high-quality. After heterogeneity tests, a value of χ^2^~exp~ = 0.39 with two degrees of freedom, and *P* = 0.821, suggested that the differences found between the studies could be due to randomness. This finding was also corroborated by an *I^2^* coefficient of 0.0% (CI 95%: 0--0.47), indicating that no OR variability was due to study heterogeneity. Both Begg\'s and Egger\'s tests were not significant (*P* = 0.117 and *P* = 0.500, respectively), indicating that there was no publishing bias. With regard to EBV, four studies compared EBV infection in depressed patients and healthy controls ([Fig. 3C](#f3){ref-type="fig"}). The studies were heterogeneous, and the most relevant ones were those by Haeri[@b19] and Johnson[@b20] due to their larger sample sizes. When all four studies were combined, an overall OR of 1.99 (CI 95%: 1.21--3.28; *P* = 0.007) was obtained for the association between EBV and depression. Therefore, depression was 1.99 times more frequent in individuals displaying the EBV marker than in individuals who did not. When only studies that used serum antibodies as the EBV infection marker were included, the result remained statistically significant with an OR of 1.96 (CI 95%: 1.18--3.24; *P* = 0.009). When heterogeneity analysis was conducted, a χ^2^~exp~ = 2.16 was obtained with three degrees of freedom and a *P* = 0.540, indicating that the differences between the studies could be due to randomness. This finding was also corroborated by an *I^2^* coefficient of 0.0% (CI 95%: 0--0.79), indicating that no OR variability was due to study heterogeneity. There was no evident publishing bias, as the Begg\'s (*P* = 0.497) and Egger\'s (*P* = 0.730) tests were not significant.

With respect to the other HHVs, no significant differences were found when comparing infection with HSV-2, CMV, or HHV-6 in depressed patients and healthy controls. As to CMV, three studies compared CMV infection by means of antibody or viral DNA in depressed patients and healthy controls ([Fig. 3D](#f3){ref-type="fig"}). The weight of the studies performed in 1974[@b18] superceeded the other two studies, as it had the largest sample size and highest quality. Significant OR values were not found for any of the studies nor for the combined OR (OR = 1.91; CI 95%: 0.89--4.09; *P* = 0.096). When heterogeneity tests were performed, a χ^2^~exp~ = 0.45 was obtained with two degrees of freedom and a *P* = 0.799, indicating that the differences between the studies can be attributed to randomness. This finding was also corroborated by an *I^2^* coefficient of 0.0% (CI 95%: 0--0.54), indicating that no OR variability was due to study heterogeneity. The Begg\'s test result was not significant (*P* = 0.117), indicating no publication bias. A similar result was obtained after Egger\'s test (*P* = 0.46).

Chlamydiaceae
-------------

Two studies of similar quality by Fellerhoff et al.[@b21][@b22] were included and used blood samples to detect the DNA of three *Chlamydiaceae* species (i.e., *C. trachomatis*, *C. pneumoniae*, and *C. psittaci*) through polymerase chain reaction (PCR) ([Fig. 4](#f4){ref-type="fig"}). A significant association was found for *C. trachomatis* with a wide 95% confidence interval (OR = 11.02; CI 95%: 1.53--79.39; *P* = 0.017; [Fig. 4A](#f4){ref-type="fig"}). However, in the cases of *C. pneumoniae* (OR = 3.32; CI 95%: 0.54--20.44; *P* = 0.196; [Fig. 4B](#f4){ref-type="fig"}) and *C. psittaci* (OR = 5.23; CI 95%: 0.55--49.28; *P* = 0.149; [Fig. 4C](#f4){ref-type="fig"}), no significant association was observed between infection with these two *Chlamydiaceae* species and depression.

Other infectious agents
-----------------------

As to hepatitis B virus (HBV), no significant differences were found (OR = 9.06; CI 95%: 0.026--3192.90; *P* = 0.461) from the analysis of two low-quality studies that compared HBV infection in depressed patients and healthy controls ([Fig. 5A](#f5){ref-type="fig"}, [Table 1](#t1){ref-type="table"}). With regard to *T. gondii*, three studies focused on the possible relationship between *T. gondii* infection and depression by comparing the detection of infection markers in samples of depressed patients and healthy controls ([Fig. 5B](#f5){ref-type="fig"}, [Table 1](#t1){ref-type="table"}). Conejero-Goldberg et al.[@b23] was limited to post-mortem brain tissue samples, and therefore, included a smaller number of cases and controls; this study was also of lower quality. After combining the different studies, no significant association was found between *T. gondii* parasitization and depression (OR = 1.36; CI 95%: 0.58--3.22; *P* = 0.483). With respect to the remaining infectious agents, results from the individual studies that analyzed the relationships between depression and infection with the hepatitis C virus (HCV), the human polyoma virus John Cunningham virus (JCV), the papovavirus BK virus (BKV), and the measles virus are also provided ([Table 1](#t1){ref-type="table"}).

Discussion
==========

From the 28 included studies in this systematic review and meta-analysis, 16 infectious agents were discovered in both depressed patients and healthy controls. The majority of included studies focused on BDV, the HHV family, the *Chlamydiaceae* family, *T. gondii*, and HBV. Scattered reports on HCV, JCV, BKV, and measles virus were also included.

Pooled analysis revealed that the majority of the 16 infectious agents were not significantly associated with depression. However, there were statistically significant associations between depression and infection with BDV, HSV-1, VZV, EBV, and *C. trachomatis*.

BDV, a neurotropic, non-cytolytic, non-segmented, negative-stranded non-retroviral RNA virus[@b24], infects a variety of animal species, including primates[@b25] and tree shrews[@b26]. BDV displays a predilection for infecting the limbic system and hippocampus[@b27], two brain regions which play important roles in affective disorders such as depression. Researchers have attempted to clarify the relationship between BDV infection and depression in numerous studies using different populations and diverse techniques; nonetheless, the relationship between BDV infection and depression remains controversial. For instance, Na[@b28] and Hornig[@b16] obtained negative results from RT-qPCR of peripheral blood mononuclear cells (PBMCs) and blood; however, persistent BDV seropositivity has been repeatedly demonstrated in a high percentage of depression patients[@b15][@b29][@b30]. Through our pooled analysis, we found that individuals who suffer from depression are 3.25 times more likely to be infected by BDV. This finding indicates that a statistically significant association between BDV infection and depression exists and requires further investigation.

HSV-1 research with respect to depression has been typically descriptive in nature and has been based on two approaches: (i) serological tests showing antibody prevalence in depressed patients and healthy controls, and (ii) brain tissue sampling to ascertain whether the presence of HSV-1 in brain cells is associated with depression. These previous studies, save one[@b18], have shown no conclusive findings[@b31][@b32]. In this study, a significant association between HSV-1 infection and depression was found. This may be due to the limitations inherent in the human brain tissue studies used in this meta-analysis. For example, after HSV-1 infection, various brain areas may have differing, scant distributions of HSV-1 particles, and with current techniques, it is difficult to detect small quantities of HSV-1 particles. Additionally, post-biopsy brain tissue processing may have affected the viral findings.

Regarding VZV, chickenpox in children has been shown to produce neurological damage in addition to viral encephalitis[@b33]. Furthermore, major depression has been associated with a marked decline in VZV-specific cellular immunity[@b34]. These previous studies[@b23][@b35], the lack of association between VZV infection and depression observed here may partly be due to the use of brain tissue for viral DNA detection, which has provided negative results in all participants assessed by this method. Therefore, detection of different tissue samples by various methods should be performed.

Several studies have focused on the relationship between EBV and depression[@b31][@b36][@b37]. Amsterdam et al.[@b38] showed no association between unrecognized chronic active EBV infection and depression; moreover, Conejero-Goldberg et al.[@b23] also failed to demonstrate an association between EBV infection and depression. However, the titers of antibodies to EBV have been shown to be significantly higher in psychiatric patients than controls[@b31]. Most notably, antibodies to EBV viral capsid antigen (EBV-VCA) have been detected in the cerebrospinal fluid (CSF) of psychiatric patients[@b31]. In addition, a direct association between EBV reactivation and maternal depression has been found among women undergoing first-trimester genetic screening[@b19]. With respect to the current study, the significant association between EBV infection and depression reported here is strongly dependent on the association reported by Johnson (n = 200)[@b20] and Haeri (n = 200)[@b19], which were the largest EBV studies by sample size as compared to the aforementioned studies by Amsterdam et al.[@b38] (n = 44) and Conejero-Goldberg et al.[@b23] (n = 29) ([Table 1](#t1){ref-type="table"}). These findings suggest that smaller sample-sized studies tend to produce negative results, and identifying a significant association between EBV infection and depression may require a sufficiently large sample size.

Only one study explored the association between HSV-2 infection and depression, which failed to show a significant association between the presence of HSV-2 DNA in brain tissue and depression. Although there were no apparent differences in the mean HSV-2 lgG antibody titers between depressed patients and healthy controls in the current study[@b32], previous research has shown that maternal exposure to HSV-2 is associated with an increased risk for psychosis among adult offspring[@b9]. This fact may be attributed to the heightened risk of HSV-2 transmission to infants exposed to asymptomatic shedding at delivery[@b39]. These previous findings suggest that HSV-2 infection at childbirth may play a role in the later development of depression; thus, further investigation on this issue is required.

CMV is a ubiquitous virus, with an especially high prevalence in lower socioeconomic status populations[@b18]. Individuals with higher CMV-specific antibody titres are more likely to be depressed and experience more overall psychological morbidity, suggesting that symptoms of depression may induce CMV reactivation[@b40]. Our negative result may be attributed to the use of brain tissue samples for the detection of viral DNA that may have been degraded.

One out of five depressed patients carry *C. trachomatis* DNA, which far exceeds the prevalence in healthy individuals, and indicates a significant association between *C. trachomatis* infection and depression. Interestingly, *C. trachomatis* produces a sexually transmitted disease (STI) as opposed to *C. pneumoniae* and *C.* psittaci, which both produce pneumonia[@b41]. Although the causal nature of the association between increased depressive symptoms and STIs has not been discerned, sexually risky behaviors may be related to dispositional characteristics, such as impulsiveness, sensation seeking, or a desire for unconventionality, that can be associated with substance abuse and depression[@b42].

This systematic review and meta-analysis showed no significant association between HBV infection and depression. Several studies have reported that mentally ill patients have a higher prevalence of HBV infection[@b43][@b44]. Unfortunately, few studies have directly examined HBV infection among depression patients with comparable healthy controls. Therefore, future research should focus on the possible relationship between HBV infection and depression.

*T. gondii* is an obligate intracellular protozoan parasite infecting one-third of the world population and dormantly resides in the brains of immunocompetent hosts[@b45]. Higher *T. gondii* immunoglobulin G titers in pregnant women have been associated with depression during pregnancy[@b46], and subclinical reactivation of *T. gondii* or immune responses to *T. gondii* have been shown worsen mood in pregnant women. From one case report, the response to antidepressant treatment improved only after adequate treatment for toxoplasma[@b47]. Nonetheless, according to the data obtained in this meta-analyses, no significant relationship exists between *T. gondii* seropositivity and recurrent mood disorder[@b45].

Finally, four viruses (HCV, JCV, BKV, and measles virus) were analyzed to determine their possible association with depression. Only two, HCV and measles virus, were shown to have a statistically significant association with depression (*P* \< 0.05). However, as these studies were one-of-a-kind and anecdotal, we were unable to draw definitive conclusions about these virus\' relationship with depression.

Based on above results, the directionality of the association between infection and depression should be concerned. We speculate that there might possibly be a causal relationship between BDV and the etiology of depression. The indirect evidence is that the overall response rate of the amantadine augmentation in the BDV-infected patients with regard to depressive symptoms was 68% after a mean of 2.9 weeks of treatment. In addition, the decrease of depression tended to correspond with the decrease in viral activity[@b48]. However, until now, there are no enough evidences that explain the directionality of the association between the other four microorganism (HSV-1, VZV, EBV, and *C. trachomatis*) and depression. Taking into account the selection bias, which come from the controls in the included studies were not completely enrolled the very same source population of cases ([Supplement](#s1){ref-type="supplementary-material"}), thus, more researches correspond to the nested case/control (CC) study design with large sample size should be performed to cope with this problem in the future.

Methods
=======

Literature search strategy
--------------------------

This study was composed of two components: a qualitative systematic review followed by a quantitative meta-analysis. A systematic review, by definition, implies an epidemiologic description of previously published articles that regards individual studies as "subjects". A computerized literature search was conducted up to May 2013 using Medline (PubMed), ISI Web of Knowledge, PsycINFO, and the Cochrane Library. No race restriction was utilized. The following logical combinations of search terms were used: ("depression", "depressive", "depressed", OR depression\*) AND (\["virus" OR virus\*\] OR \["bacterium", "bacteria", OR bacteria\*\] OR \["fungus" OR fungi\*\] OR \["parasite" OR parasite\*\]). Reference lists of all discovered articles were examined for identification of additional eligible studies.

Inclusion and exclusion criteria
--------------------------------

Included studies must have (i) enrolled patients with a current diagnosis of unipolar depression, consisting of either a primary depressive episode or recurrent depressive disorder, with the specific exclusion of patients with manic episodes, bipolar disorder, and other unclearly defined mood or affective disorders; (ii) enrolled controls who were defined as healthy individuals or those characterized by the absence of any history of psychiatric or neurological disease; and (iii) examined biochemical markers in both patients and controls. Excluded studies included non-controlled studies, animal studies, reviews, studies which did not present their results in an appropriate and/or explicit manner, and those that did not assess infectious agent(s).

Selection of studies, data extraction, and management
-----------------------------------------------------

A customized data extraction form was used. Three authors (XL, XZ and YL) independently performed the database searches, reviewed each of the retrieved abstracts, selected those that appeared to meet the study\'s inclusion criteria, and reviewed each of the selected manuscripts in full. Where a study met the inclusion criteria, they independently extracted the data from each study. The following information was extracted: microorganism, first author name, publication year, diagnostic criteria for unipolar depression, sample of detection, technique, biomarker of determination, descriptive results in each group ([Table 1](#t1){ref-type="table"}). All authors reviewed and agreed on the study inclusion and exclusion criteria, and on the selected manuscripts. Any disagreement was resolved by consensus or third-party adjudication (XL). Study quality was assessed using the Newcastle-Ottawa Quality Assessment Scale (<http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm>; updated 10 February 2010).

Statistical analysis
--------------------

The summary odds ratio (OR) was used as the effect parameter for this meta-analysis, and a 95% confidence interval (CI) was used to interpret the results. When the number of studies under analysis was greater than or equal to three (although five may be better), heterogeneity was assessed using the χ^2^ test and *I^2^*. A *P*-value of ≤0.10 was deemed statistically significant, and there were not substantial heterogeneity if a 95% CI for the *I^2^* index contains the zero percentage. *I^2^* values of 25%, 50%, and 75% represented low, moderate, and high degree of inconsistency, respectively. In cases of low heterogeneity for outcome data, a fixed-effect model was used for analysis; otherwise, a random-effect model was used. For *I^2^* values greater than 75%, strong heterogeneity dictated the performance of an additional meta-regression using the Restricted Maximum Likelihood (REML) method. In such cases and if the number of studies to be included in each subgroup was big enough (greater than or equal to three), a more detailed sub-analysis of the different subgroups was performed. Finally, Begg\'s and Egger\'s tests were used in order to check for any particular publication biases and their magnitude. Data obtained from the included studies were analyzed using the R version 3.0.1 statistical package. All tests were two-sided, and a *P* \< 0.05 was was deemed statistically significant unless otherwise specified.
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![Forest plot of studies comparing Borna disease virus (BDV) infection between depressed patients and healthy controls.\
BDV infection was shown to have a statistically significant association with depression.](srep04530-f2){#f2}

![Forest plot of studies comparing human herpes virus (HHV) infections between depressed patients and healthy controls.\
(A) herpes simplex virus-1 (HSV-1, HHV-1), (B) varciella zoster virus (VZV, HHV-3), (C) Epstein-Barr virus (EBV, HHV-4), and (D) cytomegalovirus (CMV, HHV-5). Only HSV-1, VZV, EBV infection was shown to have a statistically significant association with depression.](srep04530-f3){#f3}
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(A) *C. trachomatis*, (B) *C. pneumoniae*, and (C) *C. psittaci*. Only *C. trachomatis* infection was shown to have a statistically significant association with depression.](srep04530-f4){#f4}

![Forest plot of studies comparing two other microorganisms infections between depressed patients and healthy controls.\
(A) hepatitis B virus, (B) *Toxoplasma gondii*. Neither of them infection was shown to have a statistically significant association with depression.](srep04530-f5){#f5}

###### Analysis and Evaluation of Studies Included in the Meta-Analysis

  Microorganism                                               Study                    Diagnostic criteria        Sample          Technique    Determination   Descriptive statistics   Inferential statistics   Quality   Global OR                                                                                                                                                                          
  ----------------------------------------- ----------------------------------------- --------------------- ------------------- ------------- --------------- ------------------------ ------------------------ --------- ----------- --------------- --------------- ------------------------------------ ------------------------------------ ------------------------------ ------------------------------ ------------------------------------
  BDV                                           Amsterdam JD et al. (1985)[@b49]             DSM-III                SE               IFA            Ab                   6                       120                0         105          11.38       0.63--204.44                   4.51                                 \*\*                                                 [\*](#t1-fn2){ref-type="fn"}     3.25 (1.61--6.55; *P* = 0.001)
  Bode L et al. (1992)[@b17]                                 DSM-III                           SE                   IP               Ab              5                  358                       11               472       0.60       0.21--1.74         13.38          [\*](#t1-fn2){ref-type="fn"}                                           [\*](#t1-fn2){ref-type="fn"}                                                   
  Fu ZF et al. (1993)[@b15]                                 DSM-III-R                          SE                   WB               Ab             53                   85                       19               98        3.22       1.77--5.86         16.97                     \*\*\*                                \*\*                             \*\*\*                                                              
  Bode L et al. (1995)[@b30]                                DSM-III-R                         PBMCs          N-RT-PCR, FCM, IF   RNA, Ag, Ab         2                   1                        0                10        35.00     1.07--1141.97       3.34                       \*\*                                                                   \*\*                                                               
  Igata-Yi R et al. (1996)[@b50]                            DSM-III-R                         PBMCs              N-RT-PCR            RNA             1                   5                        0                36        19.91     0.72--552.78        3.62           [\*](#t1-fn2){ref-type="fn"}                                                       \*\*                                                               
  Salvatore M et al. (1997)[@b51]                           DSM-III-R                          BR                N-RT-PCR            RNA             0                   6                        0                10        1.62       0.03--91.81        2.60           [\*](#t1-fn2){ref-type="fn"}                                           [\*](#t1-fn2){ref-type="fn"}                                                   
  Fukuda K et al. (2001)[@b52]                               DSM-IV                            PL              WB, ECLIA, IF         Ab              1                   24                       0                45        5.57      0.22--141.99        3.77                      \*\*\*                                \*\*                              \*\*                                                               
  Bode L et al. (2001)[@b29]                                DSM-III-R                          PL                  ELISA             CIC            18                   2                        21               44        18.86      4.00--88.90        9.94                       \*\*                                                       [\*](#t1-fn2){ref-type="fn"}                                                   
  Lebain P et al. (2002)[@b53]                               DSM-IV                            SE                   IFA              Ab              3                   21                       45               245       0.78       0.22--2.72         11.98                     \*\*\*                                                                 \*\*\*                                                              
  Zou Dezhi et al. (2003)[@b54]                              CCMD-3                           PBMCs               RT-qPCR            RNA             1                   20                       0                60        8.85      0.35--225.97        3.77                       \*\*                                                                   \*\*                                                               
  Wang Zhenhai et al. (2006)[@b55]                           CCMD-3                           PBMCs               RT-qPCR            RNA             6                   47                       0                32        8.89      0.48--163.42        4.46                      \*\*\*                                                                  \*\*                                                               
  Zhao Libo et al. (2007)[@b56]                              CCMD-3                           PBMCs               RT-qPCR            RNA             3                   57                       0                120       14.67     0.75--288.75        4.30                      \*\*\*                    [\*](#t1-fn2){ref-type="fn"}                  \*\*                                                               
  Flower RL et al. (2008)[@b57]                              DSM-IV                            PL                  ELISA             Ab              5                   99                       5                214       2.16       0.61--7.64         11.90                      \*\*                                                                   \*\*                                                               
  Na KS et al. (2009)[@b28]                                  DSM-IV                           PBMCs            IFA, RT-qPCR        Ab, RNA           0                   98                       0                60        0.61       0.01--31.36        2.73                       \*\*                                                       [\*](#t1-fn2){ref-type="fn"}                                                   
  Hornig M et al. (2012)[@b16]                               DSM-IV                            BL                 RT-qPCR            RNA             0                   80                       0                80        1.00       0.02--51.01        2.73        [\*\*\*\*](#t1-fn2){ref-type="fn"}                  \*\*                             \*\*\*                                                              
  HSV-1 (HHV-1)                                  Pokorny AD et al. (1973)[@b12]               DSM-I                 SE               CF             Ab                   54                       8                35          3           0.58         0.14--2.33                   55.45                                \*\*\*                                                            \*\*                 2.26 (1.08--4.71; *P* = 0.030)
  Lycke E et al. (1974)[@b18]                                 DSM-I                            SE                   CF               Ab             31                   4                        89               51        4.44       1.48--13.30        40.28                      \*\*                     [\*](#t1-fn2){ref-type="fn"}                  \*\*                                                               
  Carter et al. (1987)[@b35]                                 DSM-IV                            BR                   HIB              DNA             0                   10                       0                21        2.05      0.04--110.55        3.15        [\*\*\*\*](#t1-fn2){ref-type="fn"}                                        [\*](#t1-fn2){ref-type="fn"}                                                   
  Conejero-Goldberg C et al. (2003)[@b23]                    DSM-IV                            BR               N-PCR, HIB           DNA             0                   3                        0                26        7.57      0.13--445.73        1.12                      \*\*\*                                                      [\*](#t1-fn2){ref-type="fn"}                                                   
  HSV-2 (HHV-2)                              Conejero-Goldberg C et al. (2003)[@b23]         DSM-IV                 BR           N-PCR, HIB         DNA                  0                        3                 0         26           7.57        0.13--445.73                                                       \*\*\*                                                [\*](#t1-fn2){ref-type="fn"}              *P* = 0.330
  VZV (HHV-3)                                      Lycke E et al. (1974)[@b18]                DSM-I                 SE               CF             Ab                   19                       16               52         88           2.01         0.95--4.25                    95.7                                 \*\*                  [\*](#t1-fn2){ref-type="fn"}               \*\*                 2.07 (1.01--4.28; *P* = 0.048)
  Carter et al. (1987)[@b35]                                 DSM-III                           BR                   HIB              DNA             0                   10                       0                21        2.05      0.04--110.55         3.2        [\*\*\*\*](#t1-fn2){ref-type="fn"}                                        [\*](#t1-fn2){ref-type="fn"}                                                   
  Conejero-Goldberg C et al. (2003)[@b23]                    DSM-IV                            BR                   HIB              DNA             0                   3                        0                26        7.57      0.13--445.73         1.1                      \*\*\*                                                      [\*](#t1-fn2){ref-type="fn"}                                                   
  EBV (HHV-4)                                   Amsterdam JD et al. (1986)[@b38]             DSM-IV                 SE               IF             Ab                   9                        9                13         13           1.00         0.30--3.33                   24.18                                \*\*\*                             \*\*                          \*\*\*                1.99 (1.21--3.28; *P* = 0.007)
  Conejero-Goldberg C et al. (2003)[@b23]                    DSM-IV                            BR               N-PCR, HIB           DNA             0                   3                        0                26        7.57      0.13--445.73        0.51                      \*\*\*                                                      [\*](#t1-fn2){ref-type="fn"}                                                   
  Johnson N et al. (2011)[@b20]                               EPDS                             SE                    ?               Ab             48                   52                       30               70        2.15       1.21--3.85         70.94                      \*\*                     [\*](#t1-fn2){ref-type="fn"}                  \*\*                                                               
  Haeri S et al. (2011)[@b19]                                DSM-IV                            SE                  ELISA             Ab             99                   1                        96                4        4.13       0.45--37.57        4.37                       \*\*                     [\*](#t1-fn2){ref-type="fn"}      [\*](#t1-fn2){ref-type="fn"}                                                   
  CMV (HHV-5)                                      Lycke E et al. (1974)[@b18]                DSM-I                 SE               CF             Ab                   24                       11               76         64           1.84         0.84--4.04                   95.68                                 \*\*                  [\*](#t1-fn2){ref-type="fn"}               \*\*                 1.91 (0.89--4.09; *P* = 0.096)
  Carter et al. (1987)[@b35]                                 DSM-IV                            BR                   HIB              DNA             0                   10                       0                21        2.05      0.04--110.55        3.19        [\*\*\*\*](#t1-fn2){ref-type="fn"}                                        [\*](#t1-fn2){ref-type="fn"}                                                   
  Conejero-Goldberg C et al. (2003)[@b23]                    DSM-IV                            BR               N-PCR, HIB           DNA             0                   3                        0                26        7.57      0.13--445.73        1.13                      \*\*\*                                                      [\*](#t1-fn2){ref-type="fn"}                                                   
  HHV-6                                      Conejero-Goldberg C et al. (2003)[@b23]         DSM-IV                 BR              N-PCR           DNA                  0                        3                 1         25           2.43         0.08--72.05                                                       \*\*\*                                                [\*](#t1-fn2){ref-type="fn"}              *P* = 0.608
  *C. trachomatis*                              Fellerhoff B et al. (2005)[@b21]             DSM-IV                 BL               PCR            DNA                  1                        5                 1         114          22.80       1.24--419.74                  32.04                                 \*\*                              \*\*                           \*\*                11.02 (1.53--79.39; *P* = 0.017)
  Fellerhoff B et al. (2007)[@b22]                           DSM-IV                            BL                   PCR              DNA             0                   4                        4                221       5.47      0.25--117.48        67.96                      \*\*                                 \*\*                              \*\*                                                               
  *C. pneumoniae*                               Fellerhoff B et al. (2005)[@b21]             DSM-IV                 BL               PCR            DNA                  1                        5                 6         109          3.63         0.36--36.20                  59.96                                 \*\*                              \*\*                           \*\*                3.32 (0.54--20.44; *P* = 0.196)
  Fellerhoff B et al. (2007)[@b22]                           DSM-IV                            BL                   PCR              DNA             0                   4                        8                217       2.84       0.14--57.16        40.04                      \*\*                                 \*\*                              \*\*                                                               
  *C. psittaci*                                 Fellerhoff B et al. (2005)[@b21]             DSM-IV                 BL               PCR            DNA                  0                        6                 2         113          3.49         0.15--80.49                  73.07                                 \*\*                              \*\*                           \*\*                5.23 (0.55--49.28; *P* = 0.149)
  Fellerhoff B et al. (2007)[@b22]                           DSM-IV                            BL                   PCR              DNA             0                   4                        2                223       9.93      0.41--238.04        26.93                      \*\*                                 \*\*                              \*\*                                                               
  HBV                                          Faridullah Shah et al. (2004)[@b58]           DSM-IV                 BL              ELISA           Ag                   3                       132               71        1897          0.61         0.19--1.95                    53.4                                 \*\*                                                             \*\*               9.06 (0.026--3192.90; *P* = 0.461)
                                                Alvarado Esquivel C (2005)[@b59]             DSM-IV                 SE              ELISA         Ag, Ab                 0                        2                 2        2505         200.44       7.54--5326.21                  46.6                                 \*\*                                                             \*\*                                
  *T. gondii*                                Conejero-Goldberg C et al. (2003)[@b23]         DSM-IV                 BR              N-PCR           DNA                  0                        3                 0         26           7.57        0.13--445.73                   1.28                                \*\*\*                                                [\*](#t1-fn2){ref-type="fn"}     1.36 (0.58--3.22; *P* = 0.483)
  Alvarado-Esquivel C et al. (2006)[@b60]                    DSM-IV                            SE                  ELISA             Ab              1                   2                        16               164       5.13       0.44--59.67        3.96                      \*\*\*                                \*\*                  [\*](#t1-fn2){ref-type="fn"}                                                   
  Cetinkaya Z et al. (2007)[@b61]                            DSM-IV                            SE                  ELISA             Ab             12                   38                       11               39        1.12       0.44--2.84         94.76                      \*\*                     [\*](#t1-fn2){ref-type="fn"}                  \*\*                                                               
  HCV                                          Faridullah Shah et al. (2004)[@b58]           DSM-IV                 BL              ELISA           Ab                   31                      104               124       1844          4.43         2.85--6.89                                                         \*\*                                                             \*\*                          *P* \< 0.001
  JCV                                              Carter et al. (1987)[@b35]                DSM-IV                 BR               HIB            DNA                  0                        10                0         21           2.00         0.11--35.09                                         [\*\*\*\*](#t1-fn2){ref-type="fn"}                                  [\*](#t1-fn2){ref-type="fn"}              *P* = 1.000
  BKV                                              Carter et al. (1987)[@b35]                DSM-IV                 BR               HIB            DNA                  0                        10                0         21           2.00         0.11--35.09                                         [\*\*\*\*](#t1-fn2){ref-type="fn"}                                  [\*](#t1-fn2){ref-type="fn"}              *P* = 1.000
  Measles virus                                    Lycke E et al. (1974)[@b18]                DSM-I                 SE               CF             Ab                   14                       21               84         56           0.44         0.21--0.95                                                         \*\*                  [\*](#t1-fn2){ref-type="fn"}               \*\*                          *P* = 0.033
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Abbreviations: EPDS, Edinburgh Depression Scale; DSM, Diagnostic and Statistical Manual of Mental Disorders; CCMD-3, Classification and Diagnostic Criteria of Mental Disorders in China; HHV-1(HSV-1), herpes simplex virus-1; HHV-2 (HSV-2), herpes simplex virus-2; HHV-3 (VZV), varicella zoster virus; HHV-4 (EBV), Epstein-Barr virus; HHV-5 (CMV), cytomegalovirus; HHV-6, roseolovirus; HBV, hepatitis B virus; BDV, Borna disease virus; *C. trachomatis*, *Chlamydophila trachomatis*, *C. pneumoniae*, *Chlamydophila pneumoniae*; *C. psittaci*, *Chlamydophila psittaci*; *T. gondii*, *Toxoplasma gondii*; HCV, hepatitis C virus; JCV, John Cunningham virus; BKV, BK virus; SE, serum; PL, plasma; BR, brain biopsy, BL, blood; PBMCs, peripheral blood mononuclear cells; PCR, polymerase chain reaction; N-PCR, nested-polymerase chain reaction; RT-PCR, reverse transcriptase polymerase chain reaction; N-RT-PCR, nested reverse transcription polymerase chain reaction; RT-qPCR, real-time reverse transcriptase polymerase chain reaction; HIB, hybridization; ELISA, enzyme-linked immunosorbent assay; WB, Western blot; ECLIA, electrochemiluminescence immunoassay; FCM, flow cytometric analysis; EIA, enzyme immunoassay; IF, immunofluorescence; IFA, immunofluorescence assay; IP, immunoprecipitation; CF, complement fixation antibodies; NT, neutralizing antibodies; ?, unknown; DNA, deoxyribonucleic acid; RNA, ribonucleic acid; CIC, circulating immune complexes; Ag, antigen; Ab, antibody; +, positive; −, negative; S, Selection; C, Comparability; E, Exposure.

Asterisks indicate the level of study quality from low quality (\*) to (\*\*\*\*) high quality.
